Hi R&P,
I did not see anything in the article that indicated that a combination of CAR-T and PNOC study drugs was considered.
Where did you find this?
My main take-away from this article is that, while CAR-T could be a promising future treatment alternative, it still has a long way to go and early trial results are far less promising than the initial reports from paxalisib mono or paxalisib and ONC201 combo in DIPG.
Talking about DIPG, the latest interview with JG in * was promising in my view when he said:
"We’ll have to look at the data and talk to agencies like the US FDA and the TGA here in Australia – but they are generally open to having these discussions,”
https://unauthorised investment advice/health/after-a-successful-4-5-million-cap-raise-and-with-cancer-trial-results-to-come-kazia-is-optimistic-for-2023/It indicates to me that regulatory discussions on paxalisib in DIPG can happen far sooner than at the end of the combo DIPG trial.
